National Comprehensive Cancer Network





NCCN Oncology Research Program (ORP)
NCCN and Lilly Quality of Care in Gastric Cancer Opportunity: Submit by October 24, 2018
ORP Recent News
ORP Affiliate Research Consortium
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

NCCN ORP Scientific Publications

Principal Investigator NCCN Member Institution Title Publication
Tanios Bekaii-Saab, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas Cancer Chemotherapy and Pharmacology
Marc C. Chamberlain, MD Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/University of Washington Salvage therapy with single agent bendamustine for recurrent glioblastoma Journal of Neuro-Oncology
Patrick Creaven, MD, PhD Roswell Park Comprehensive Cancer Center A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer Cancer Chemotherapy and Pharmacology
Long H. Dang, MD, PhD University of Michigan Comprehensive Cancer Center Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment Molecular Cancer Therapeutics
Grace Dy, MD Roswell Park Comprehensive Cancer Center Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer Journal of Thoracic Oncology
Matthew G. Fury, MD, PhD Memorial Sloan Kettering Cancer Center A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer and Chemotherapy Pharmacology
Manuel Hidalgo, MD, PhD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Assessment of Celecoxib Pharmacodynamics in Pancreatic Cancer Molecular Cancer Therapeutics
Renuka Iyer, MD Roswell Park Comprehensive Cancer Center Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study British Journal of Cancer
Milind Javle, MD Roswell Park Comprehensive Cancer Center Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil Clinical Cancer Research
Andrew Ko, MD UCSF Helen Diller Family Comprehensive Cancer Center Optimizing the Administration of Fixed-Dose Rate Gemcitabine Plus Capecitabine Using an Alternating-week Schedule: A Dose Finding and Early Efficacy Study in Advanced Pancreatic and Biliary Carcinomas American Journal of Clinical Oncology
Razelle Kurzrock, MD The University of Texas MD Anderson Cancer Center Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin-Bound Paclitaxel in Cancer Patients with Predominant Hepatic Metastases: Toxicity, Pharmacokinetics, and Activity Molecular Cancer Therapeutics
Daniel Laheru, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer Investigational New Drugs
Rachel Layman, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Pneumocystis jiroveci Pneumonia in an Atypical Host. Clinical Breast Cancer
Robert Maki, MD, PhD Memorial Sloan Kettering Cancer Center Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas Journal of Clinical Oncology
Wells Messersmith, MD Johns Hopkins Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer Investigational New Drugs
James W. Mier, MD Beth Israel Deaconess Medical Center Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling Molecular Cancer Therapeutics
Stacy Moulder, MD, MSCI The University of Texas                      MD Anderson Cancer Center Phase 2 Study of Gemcitabine and Irinotecan in Metastatic Breast Cancer with Correlatives to Determine Topoisomerase I Localization as a predictor of response Cancer
Brian Rini, MD UCSF Helen Diller Family Comprehensive Cancer Center Maximal COX-2 Immunostaining Predicts Clinical Response to Celecoxib and Interferon Alpha Therapy in Metastatic Renal Cell Carcinoma Cancer
M. Wasif Saif, MD, MBBS University of Alabama at Birmingham Comprehensive Cancer Center A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors Cancer Chemotherapy and Pharmacology
M. Wasif Saif, MD, MBBS Yale University School of Medicine Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies Phytomedicine
Manisha Shah, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma The Journal of Clinical Endocrinology & Metabolism
Manisha Shah, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute High-dose celecoxib does not improve survival of patients with differentiated thyroid cancer Nature Clinical Practice Endocrinology & Metabolism
Charles L. Shapiro, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Phase II Study of Sequentially Administered Low-dose Mitomycin-C (MMC) and Irinotecan (CPT-11) in Women with Metastatic Breast Cancer (MBC) Annals of Oncology
Charles L. Shapiro, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer Clinical Breast Cancer
Przemyslaw Twardowski, MD City of Hope National Medical Center Biologic Markers of Angiogenesis: Circulating Endothelial Cells in Patients with Advanced Malignancies Treated on Phase I Protocol with Metronomic Chemotherapy and Celecoxib Cancer Investigation
Sam S. Yoon, MD Massachusetts General Hospital Efficacy of Sunitinib and Radiotherapy in  Genetically Engineered Mouse Model of Soft Tissue Sarcoma International Journal of Radiation Oncology* Biology*Physics

 

Bibliography: NCCN Oncology Research Program Manuscripts

Bibliography: NCCN Oncology Research Program Abstracts